Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of peripheral T-cell lymphoma (PTCL)
22. Dezember 2017 08:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation...
Rhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for RP6530 (tenalisib), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL)
09. Dezember 2017 08:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 09, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for...
Rhizen Pharmaceuticals S.A. announces clinical and preclinical data presentations at the upcoming 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, GA, USA
05. Dezember 2017 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that updated data for RP6530 (tenalisib), the Company’s highly selective and orally...
Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class oral small molecule inhibitor of calcium release-activated calcium (CRAC) channel at 2017 AACR-NCI-EORTC International Conference, USA
24. Oktober 2017 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class CRAC channel inhibitor in hematological...
Rhizen Pharmaceuticals Announces Exclusive Worldwide License Agreement for the Development and Commercialization of a Dual PI3K-delta gamma Inhibitor
09. Dezember 2015 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland , Dec. 09, 2015 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announced today that they have entered into an exclusive, worldwide license agreement with Novartis for...
Rhizen Pharmaceuticals S.A. announces initiation of Phase 2 study of RV1001 in dogs with T- or B-cell Lymphoma
22. September 2015 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. has announced the initiation of Phase 2 study of RV1001, a novel, oral selective inhibitor of PI3K...
Rhizen Pharmaceuticals S.A. to present Phase 1 clinical and additional preclinical data of RP6530 (dual PI3K delta/gamma inhibitor) in hematological malignancies
03. Dezember 2014 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces Phase 1 clinical and
additional preclinical data presentations for RP6530, a novel dual
PI3K...
Rhizen Pharmaceuticals S.A. to present preclinical data of RP6530 (dual PI3K delta/gamma inhibitor) in Multiple Myeloma
18. November 2014 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces a poster presentation for
RP6530, a novel dual PI3K delta/gamma inhibitor in Multiple
Myeloma.
...
Rhizen Pharmaceuticals Announces Out-licensing Agreement for TGR-1202, a Novel Next Generation PI3K-delta Inhibitor
23. September 2014 09:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 23, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. today announced an out-licensing
agreement for TGR-1202, a novel next generation PI3K-delta
inhibitor. TG...
Rhizen Pharmaceuticals S.A. to present preclinical data of their first-in-class inflammation assets, RP6503 and RP3128 for treatment of various respiratory diseases
03. September 2014 05:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces data for their lead
first-in-class inflammation/auto-immune assets, RP6503 and RP3128
in...